Could a shorter drug course beat a longer one for a deadly fungal infection?
NCT ID NCT07743593
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing whether a 10-week course of fluconazole works as well as the standard 24-week course for people with HIV who have a cryptococcal infection in their blood (antigenemia) but no symptoms. It also compares starting HIV medications right away versus waiting 14 days. The goal is to see which approach helps people survive without developing meningitis or needing hospitalization. The study involves 505 adults in Uganda and follows them for 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fluconazole and antiretroviral therapy (ART)
- What this could lead to
- If successful, this could lead to shorter, simpler treatment regimens for cryptococcal antigenemia, reducing side effects and improving outcomes for people with HIV.
- What could go wrong
- The trial is still in progress, and results may not confirm that the shorter regimen is as effective. There are risks of side effects from fluconazole and potential complications from ART timing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYPTOCOCCAL ANTIGENEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Infectious Diseases Institute, Makerere University
Kampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo
- Long-acting HIV shot studied in patients with severe kidney problems